Prostate cancer diagnosis procedure relies on unspecific measures such as PSA (prostate-specific antigen) levels and DRE (digital rectal examination), followed by biopsy2, where disease aggressiveness assessment is based on the Gleason Score. This evidence concerns the gene KLK3 and prostate carcinoma.